Key result
After exercise stress testing, 16.7% of patients with Brugada syndrome who were initially eligible for a subcutaneous implantable cardioverter-defibrillator lost electrocardiographic eligibility.
Why the study?
To evaluate electrocardiographic eligibility for subcutaneous implantable cardioverter-defibrillator placement after exercise stress testing in patients with Brugada syndrome.
Does exercise stress testing alter electrocardiographic eligibility for subcutaneous implantable cardioverter-defibrillator placement in patients with Brugada syndrome?
Cross-Sectional (n=35)
Does exercise stress testing alter electrocardiographic eligibility for subcutaneous implantable cardioverter-defibrillator placement in patients with Brugada syndrome?
Exercise stress testing reduces S-ICD eligibility in a significant proportion of Brugada syndrome patients, highlighting the need for post-exercise screening to avoid inappropriate therapies.
Screening after exercise may identify additional ineligible BrS patients for S-ICD; leaves open whether routine testing should change practice.
Brugada syndrome (BrS) is a channelopathy associated with ventricular arrhythmias and sudden cardiac death. In patients at high risk of sudden death, an implantable cardioverter-defibrillator is indicated. Subcutaneous implantable cardioverter-defibrillators (S-ICDs) are an alternative to transvenous systems, with reduced risk of infection and complications associated with system extraction or explantation. To test electrocardiographic eligibility for S-ICD placement after exercise stress testing (EST) in patients with BrS. The sample included 35 consecutive patients with BrS. Electrocardiographic eligibility was assessed using the Boston Scientific model 2889 EMBLEM™ S-ICD automated screening tool, in four phases: decubitus and orthostatism, and before and after EST. Those who had at least one acceptable vector in the four measurements were considered eligible. In this study, 71.4% of patients were male and mean age was 53.86±12 years. In screening prior to EST, 14.3% of patients (n=5) were not eligible for an S-ICD. There was a statistically significant association between ineligibility and presence of complete right bundle branch block and history of syncope. After EST, 16.7% of initially eligible patients no longer had eligible vectors (n=5). In this study, 16.7% of patients previously eligible for an S-ICD were no longer eligible after EST. This result demonstrates the importance of screening after EST in all patients with BrS and with indication for an S-ICD, and may influence decisions concerning which ICD to implant or whether to institute pharmacological measures that avoid inappropriate therapies. A síndrome de Brugada (SBr) é uma canalopatia associada ao desenvolvimento de arritmias ventriculares e morte súbita cardíaca. Pacientes com alto risco devem ser orientados para a colocação um cardioversor-desfibrilhador. O cardioversor-desfibrilhador implantável subcutâneo (CDI-S) é uma alternativa ao sistema transvenoso, com menor risco de infeção e complicações associadas à extração/explante do sistema. Testar a elegibilidade eletrocardiográfica para colocação de CDI-S após prova de esforço (PE) em pacientes com SBr. A amostra incluiu 35 pacientes, consecutivos, com SBr. A elegibilidade eletrocardiográfica foi avaliada pela ferramenta de rastreio automática, Boston-Emblem S-ICD (Modelo 2889)®, em quatro fases: decúbito e ortostatismo, antes e depois da PE – foram considerados elegíveis indivíduos que tinham pelo menos um vetor aceitável nas quatro fases. Neste estudo, 71,4% dos pacientes eram do sexo masculino, com idade média de 53,86±12 anos. No rastreio anterior à PE, 14,3% dos pacientes (n=5) não eram elegíveis para o implante de CDI-S. Demonstrou-se uma associação significativa entre não elegibilidade e a presença de bloqueio de ramo direito e história de síncope. Após a PE, 16,7% dos pacientes inicialmente elegíveis deixaram de ter vetores aceitáveis para a implantação de CDI-S (n=5). Neste estudo, 16,7% dos pacientes previamente elegíveis para CDI-S deixaram de o ser após a PE. Estes resultados demonstram a relevância do rastreio após PE em todos os pacientes com SBr e com indicação para CDI-S, influenciando a decisão do sistema a implantar ou medidas farmacológicas que evitem casos de terapias inadequadas.
No takes yet. Share an insight, caveat, or question.
Hafe et al. (2021) conducted a cross-sectional in Brugada syndrome (n=35). Exercise stress testing vs. Baseline (prior to exercise stress testing) was evaluated on Loss of electrocardiographic eligibility for S-ICD placement. After exercise stress testing, 16.7% of patients with Brugada syndrome who were initially eligible for a subcutaneous implantable cardioverter-defibrillator lost electrocardiographic eligibility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: